UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934 (Amendment No. 1) *

	Selecta Biosciences, Inc.
	(Name of Issuer)
	Common Stock, par value \$0.0001
	(Title of Class of Securities)
	816212104
	(CUSIP Number)
	December 31, 2018
	(Date of Event which Requires Filing of this Statement)
Ch	eck the appropriate box to designate the rule pursuant to which this Schedule is filed:
	Rule 13d-1(b)
\boxtimes	Rule 13d-1(c)
	Rule 13d-1(d)
*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
	The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP I	CUSIP No. 816212104						
1	NAMES OF REPORTING PERSONS						
•	Vivo Capital VIII, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)						
-	(a) □ (b) □						
2	SEC USE ONLY						
3							
_	CITIZENSHIP OR PLACE OF ORGANIZATION						
4	Delaware						
		-	SOLE VOTING POWER				
NUM	BER OF	5	546,054 ⁽¹⁾				
	ARES	_	SHARED VOTING POWER				
	ICIALLY IED BY	6					
	ACH		SOLE DISPOSITIVE POWER				
	ORTING RSON	7	546,054 ⁽¹⁾				
	ITH		SHARED DISPOSITIVE POWER				
		8					
1	AGGREGA	TE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9							
	546,054 (1)						
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)						
	DED CENTE OF CLASS DEPONDED BY A MOUNTE IN DOLL (S)						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	1.3% (2)						
12	TYPE OF REPORTING PERSON (See Instructions)						
	00						

- (1) The shares of common stock, par value \$0.0001 per share (the "Common Stock") are held of record by Vivo Capital Fund VIII, L.P., and Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P.
- Based on 42,471,776 shares of Common Stock of the Issuer outstanding, as disclosed in the prospectus supplement filed by the Issuer on January 24, 2019, pursuant to Rule 424(b)(5), which forms part of the Issuer's Registration Statement on Form S-3 (File No. 333-219900).

I тем 1.	(a)	Name	of Issuer:				
		Selecta	Biosciences, Inc				
	(b)	Addres	ss of Issuer's Principal Executive Offices:				
		480 Ar	senal Way				
		Waterto	own, MA 02472				
Ітем 2.	(a)	NAME (of Person Filing:				
		Vivo C	apital VIII, LLC				
	(b)	Address of Principal Business Office or, if None, Residence:					
		505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301					
	(c)	CITIZEN	NSHIP:				
		Vivo Capital VIII, LLC is a Delaware limited liability company.					
	(d)	TITLE O	of Class of Securities:				
		Comm	on Stock				
	(e)	CUSIF	Number:				
		816212	2104				
Ітем 3.	IF T	If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:					
	(a)		Broker or dealer registered under Section 15 of the Act.				
	(b)		Bank as defined in Section 3(a)(6) of the Act.				
	(c)		Insurance company as defined in Section 3(a)(19) of the Act.				
	(d)	(d) Investment company registered under Section 8 of the Investment Company Act of 1940.					
	(e)		An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);				
	(f)		An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);				
	(g)		A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);				
	(h)		A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;				
	(i)		A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;				
	(j)		A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);				
	(k)	(k) \square Group, in accordance with § 240.13d-1(b)(l)(ii)(K).					
	If fili	ng as a n	ion-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution:				
	Not A	pplicabl	le.				

Item 4. Ownership.

(a) Amount beneficially owned:

The shares of Common Stock are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., as follows:

- Vivo Capital Fund VIII, L.P.: 479,800 shares
- Vivo Capital Surplus Fund VIII, L.P.: 66,254 shares

Vivo Capital VIII, LLC is the general partner of both Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. The voting members of Vivo Capital VIII, LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(b) Percent of class:

1.3%

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote: 546,054
 - (ii) Shared power to vote or to direct the vote: 0
 - (iii) Sole power to dispose or to direct the disposition of: 546,054
 - (iv) Shared power to dispose of or to direct the disposition of: 0
- Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

Not Applicable.

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. CERTIFICATIONS.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

SIGNATURE

correct.	After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and					
	Vivo Capital VIII, LLC					
	February 14, 2019 (Date)					
	/s/ Albert Cha (Signature)					
	Managing Member (Title)					